Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus best supportive care vs placebo plus best supportive care in refractory metastatic colorectal cancer
2012-000095-42Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Nintedanib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Jun 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-000095-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000095-42.